Back to Top
TAKEDA TAK-620-2004 SUBJECT Screenshot 0
TAKEDA TAK-620-2004 SUBJECT Screenshot 1
TAKEDA TAK-620-2004 SUBJECT Screenshot 2
TAKEDA TAK-620-2004 SUBJECT Screenshot 3
Free website generator for mobile apps; privacy policy, app-ads.txt support and more... AppPage.net

About TAKEDA TAK-620-2004 SUBJECT

A Phase 3, open-label, single-arm, repeated-dose
study to evaluate the safety and tolerability,
pharmacokinetics, and antiviral activity of
maribavir for the treatment of cytomegalovirus
(CMV) infection in children and adolescents who
have received a hematopoietic stem cell
transplant (HSCT) or a solid organ transplant
(SOT)

Similar Apps

Medable Participant App

Medable Participant App

4.4

Today’s rapidly changing healthcare landscape presents new challenges and disruptions to patient...

I8F-MC-GPHJ PATIENT

I8F-MC-GPHJ PATIENT

0.0

A Phase 3b/4, Randomized Study in Adults w/Obesity or Overweight w/Weight-Related Comorbidities...

NN7769-4532 Participant

NN7769-4532 Participant

0.0

This app is specifically intended for study participants in the Frontier4 (NN7769-4532)...

CA055-026

CA055-026

0.0

This app is specifically intended for study participants in the Bristol Myers...

CA116-001

CA116-001

0.0

You are invited to participate in the Bristol Myers Squibb CA116-001 study....

BELIEVE

BELIEVE

0.0

You are invited to participate in the Versanis VER201-PH2-031 study...